Senior Medical Director, Clinical Research
bluebird bio, Inc
Alpert School of Medicine at Brown University
Cambridge, Massachusetts, United States
Anjulika Chawla, MD, FAAP, is a Medical Director in Medical Affairs and the US SCD lead at bluebird bio, working on gene addition therapy for SCD. Her job is to bring in the patient and provider voice to guide in development of clinical trials, understanding the unmet need, and to determine what role that gene therapy could potentially bring to address this need. She is a practicing pediatric hematologist/oncologist of almost 20 years at Hasbro Children’s Hospital in Providence, RI, and has cared for over 200 kids and young adults with sickle cell and thalassemia. She is also a Professor of Pediatrics at the Warren Alpert Medical School at Brown University, and loves to teach anyone about sickle cell and thalassemia. She is mother of four children, and has a supportive husband and family. Her goal in her work life is to put herself out of business by enabling curative intent therapies for people with cancer and blood diseases, now more specifically focused on gene addition therapy for sickle cell disease.
Disclosure information not submitted.
Lovotibeglogene Autotemcel Gene Therapy For Sickle Cell Disease: 60 Months Follow-Up
Saturday, June 8, 2024
8:45 AM – 9:00 AM ET